Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis

June 14th 2022


HOUSTON, June 14, 2022 /PRNewswire/ -- Cellenkos, Inc., a privately held, clinical stage biotech company that focuses on developing transformative T regulatory cell therapies for rare inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1b, open-label study of CK0804 as an add on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.

https://www.prnewswire.com/news-releases/cellenkos-receives-fda-clearance-of-investigational-new-drug-ind-application-for-ck0804-as-add-on-therapy-to-ruxolitinib-for-the-treatment-of-myelofibrosis-301567229.html